August 13, 2026 12:15 PM GMT Ascendis Pharma A/S | North America M Update First Take: 2Q26 Yuviwel Launch in Focus Key Takeaways Yorvipath sales were 252M euros (cons. est. 249.6M, MSe: 245M), Skytrofa sales were ~55M euros (cons. est. 50.7M, MSe: 52M). Yorvipath sales show continued steady growth, Yuviwel launch shows early uptake. Key takeaways: [1] Yorvipath launch advances. Yorvipath is now available commercially or through named patient programs in >35 countries. [2] >220 unique YUVIWEL patient enrollm ...